Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Blonanserin on Social and Cognitive Functions in First Episode Schizophrenia
NCT03784222Phase 4Terminated
- Sponsor
- Sumitomo Pharma
- Start
- Jan 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of blonanserin in schizophrenia (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Personal and Social Performance Score at 26 weeks. Started Jan 2019; status: terminated.
02
Drugs
blonanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03784222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784222.